Link copied to clipboard!
meddo

Meddo raises $3 million in Pre-Series A funding led by SRI Capital

S Singh
S Singh
· 2 min read

New Delhi, September 17, 2019: Meddo, India’s first (and now, largest) 360 degree connected health platform has raised $3 million in their Pre- Series A  funding led by SRI Capital with participation from growX Ventures, LetsVenture, Jitendra Gupta (Co-founder Citrus Pay) and Venture Gurukool, among others.

The Gurugram based startup currently has over 400 doctors and 200 clinics and is currently operational in Delhi NCR. Meddo works closely with all dominant NABL accredited diagnostic lab partners across the city. They work with 250 trained peri clinical staff for in clinic and at home sample collection and have served more than 1,50,000 customers so far.

Meddo was founded in June 2018 by Saurabh Kochhar (ex-Founder & CEO of Foodpanda and Printvenue; IIT & IIM alumnus) and Dr Naveen Nishchal (co-founder, Cygnus Hospitals and a Harvard graduate). The platform functions in offline and online space – through standalone doctor establishments with the central objective of bringing together all healthcare needs for the patients onto a single platform, bringing convenient and comprehensive care into healthcare.

Speaking on the funding, Saurabh Kochhar, Co-founder, Meddo said “Our vision is to fundamentally change how healthcare is delivered in our country; starting with the largest (USD 160 bn+) and most unorganised segment, out-patient care. We have seen unprecedented growth within the last 7 months that we have been operational, and this funding helps us further that growth and invest in the right team and technology ”

Shweta Singh, Principal, SRI Capital said “Meddo is addressing a fundamental gap in India’s healthcare ecosystem by bringing Doctor run clinics on to its platform and standardising service levels to provide patients with an offering they can trust. We are confident in Saurabh and Dr. Nishchal’s ability to execute and create a healthcare offering that Doctors, patients and healthcare providers love.”

Jitendra Gupta, Co-founder, Citrus Pay and one of the early investors in Meddo said “I invested in Meddo very early on, as I believed in Saurabh and Dr Naveen’s vision and their demonstrated capability to execute. I have been thoroughly impressed with their incredible growth numbers over the last 6 months”

Manu Rikhye, Partner, growX Ventures said “Health is one of the most technologically underpenetrated and sectors in India with its peculiar challenges. We believe Meddo’s unique approach of aggregating standalone establishments using technology to bring in convenience, quality and excellence in the standards of care has great potential to overcome those challenges.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk